SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
PARIS and CAMBRIDGE, Mass., Oct. 04, 2017 -- Lysogene (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in the following investor events in the upcoming weeks:
| October | |||
| |||
| Date: | Wednesday, October 11 | ||
| Time | 3:45pm Eastern Time | ||
| Location: | Westin New York Grand Central, Assembly Room | ||
| |||
| Date: | Thursday, October 12 | ||
| Time: | 2:30pm Eastern Time | ||
| Location: | Westin New York Grand Central | ||
| |||
| Date: | Friday, October 13 | ||
| Time: | 12:00pm – 1:30pm Eastern Time | ||
| Location | Lotte New York Palace Hotel | ||
| Webcast: http://lifesci.rampard.com/20171013/reg.jsp | |||
| November | |||
| |||
| Date: | Tuesday, November 14 & Wednesday, November 15 | ||
| Time: | TBD | ||
| Location | Waldorf Hilton | ||
About Lysogene
Lysogene (www.lysogene.com) is a global biopharma leader in orphan CNS disease research and development. Lysogene has generated five non-cumulative years of clinical safety data to show the efficiency of a direct delivery route to the CNS with its initial gene therapy trial for MPS IIIA. Lysogene has recently completed the enrollment for the first multi-national observational study in MPS IIIA which will function as the non-concurrent control for the first pivotal trial for MPS IIIA in H1 2018. Lysogene also plans a clinical trial for GM1 Gangliosidosis for 2019. Lysogene has obtained orphan drug designation from the EMA and FDA and rare pediatric designation by the FDA for both programs.
Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475).
For more information: www.lysogene.com.
Contacts
| Media: | Investors: | |
| Europe | ||
| Annie-Florence Loyer | Chris Maggos | |
| NewCap | LifeSci Advisors | |
| [email protected] | [email protected] | |
| + 33 6 88 20 35 59 | +41 79 367 6254 | |
| + 33 1 44 71 00 12 | ||
| North America | ||
| Marion Janic | ||
| RooneyPartners | ||
| [email protected] | ||
| + 1 (212) 223-4017 |
